Latest News

Multinational media and entertainment corporation Paramount (NASDAQ:PARA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 6.4% year on year to $7.19 billion. Its non-GAAP profit of $0.29 per share was 12% above analysts’ consensus estimates.

Laser company nLIGHT (NASDAQ:LASR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 16% year on year to $51.67 million. On top of that, next quarter’s revenue guidance ($56 million at the midpoint) was surprisingly good and 11.7% above what analysts were expecting. Its non-GAAP loss of $0.04 per share was 78.7% above analysts’ consensus estimates.

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts’ consensus estimates.

Outdoor lifestyle and equipment company Clarus (NASDAQ:CLAR) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 12.8% year on year to $60.43 million. Its non-GAAP loss of $0.02 per share was $0.03 below analysts’ consensus estimates.

Skincare company BeautyHealth (NASDAQ:SKIN) announced better-than-expected revenue in Q1 CY2025, but sales fell by 14.5% year on year to $69.6 million. On the other hand, next quarter’s revenue guidance of $73.5 million was less impressive, coming in 2.9% below analysts’ estimates. Its GAAP loss of $0.08 per share was 37.6% above analysts’ consensus estimates.

E-commerce florist and gift retailer 1-800-FLOWERS (NASDAQ:FLWS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 12.6% year on year to $331.5 million. Its non-GAAP loss of $0.71 per share was significantly below analysts’ consensus estimates.

Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came in 3.1% above analysts’ estimates. Its GAAP loss of $0.50 per share was 21.4% above analysts’ consensus estimates.

Mobile game developer Skillz (NYSE:SKLZ) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 11.2% year on year to $22.41 million. Its GAAP loss of $0.92 per share was 16.4% above analysts’ consensus estimates.

Composite decking and railing products manufacturer Trex Company (NYSE:TREX) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 9% year on year to $340 million. Its GAAP profit of $0.56 per share was 4.1% below analysts’ consensus estimates.

Logistics solutions provider Hub Group (NASDAQ:HUBG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 8.4% year on year to $915.2 million. The company’s full-year revenue guidance of $3.8 billion at the midpoint came in 5.6% below analysts’ estimates. Its GAAP profit of $0.44 per share was 3% above analysts’ consensus estimates.

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts’ consensus estimates.

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was less impressive, coming in 3.6% below analysts’ estimates. Its GAAP loss of $0.28 per share was 40.6% above analysts’ consensus estimates.

Medical device company ICU Medical (NASDAQ:ICUI) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.7% year on year to $604.7 million. Its non-GAAP profit of $1.72 per share was 34.4% above analysts’ consensus estimates.

Boutique fitness studio franchisor Xponential Fitness (NYSE:XPOF) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 3.3% year on year to $76.88 million. The company expects the full year’s revenue to be around $320 million, close to analysts’ estimates. Its non-GAAP loss of $0.20 per share was significantly below analysts’ consensus estimates.

Experiential tourism company Pursuit Attractions and Hospitality (NYSE:PRSU) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 86.3% year on year to $37.58 million. Its non-GAAP loss of $0.96 per share was 31.5% below analysts’ consensus estimates.

Home security and automation software provider Alarm.com (NASDAQ:ALRM) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 7% year on year to $238.8 million. The company expects the full year’s revenue to be around $983.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.54 per share was 13.8% above analysts’ consensus estimates.

Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per share was 3.2% above analysts’ consensus estimates.

Smart security company Arlo (NYSE:ARLO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 4.1% year on year to $119.1 million. Its non-GAAP profit of $0.15 per share was 28.2% above analysts’ consensus estimates.

Energy drink company Monster Beverage (NASDAQ:MNST) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 2.3% year on year to $1.85 billion. Its non-GAAP profit of $0.47 per share was 2.2% above analysts’ consensus estimates.

Foodservice packaging supplier Karat Packaging (NASDAQ:KRT) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 8.4% year on year to $103.6 million. Guidance for next quarter’s revenue was better than expected at $123.9 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 5.3% above analysts’ consensus estimates.

Healthcare distributor and services company McKesson (NYSE:MCK) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 18.9% year on year to $90.82 billion. Its non-GAAP profit of $10.12 per share was 3% above analysts’ consensus estimates.

Real estate technology company Compass (NYSE:COMP) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 28.7% year on year to $1.36 billion. Next quarter’s revenue guidance of $2.08 billion underwhelmed, coming in 1.5% below analysts’ estimates. Its non-GAAP loss of $0.09 per share was significantly below analysts’ consensus estimates.

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 37.7% below analysts’ consensus estimates.